Avaí Bio Partners with Austrianova to Revolutionize Diabetes Therapy Through Insulin-Producing Cells
In a groundbreaking development for diabetes therapy, Avaí Bio, Inc., an emerging biotechnology firm, has joined forces with Austrianova, a leading cell encapsulation company, to create a revolutionary treatment for diabetes through insulin-producing cells. This collaboration was made public during a press conference held on July 21, 2026, in Las Vegas.
Avaí Bio has gained recognition for its innovative cell-based therapies targeting not only diabetes but also age-related disorders and anti-aging concerns. The focus of this newly formed partnership lies in their joint venture called Insulinova, which was established in late 2025. Insulinova aims to pioneer a cell-based therapy that integrates genetically modified cells that function as insulin producers with Austrianova’s proprietary Cell-in-a-Box® technology. This unique encapsulation technique promises to supply a constant flow of insulin in response to the body's varying needs, providing a more natural alternative for individuals afflicted with type 1 diabetes and those with insulin-dependent type 2 diabetes.
Chris Winter, CEO of Avaí Bio, expressed his enthusiasm for the recently signed agreement, stating, "This partnership is a pivotal advancement for Insulinova and our diabetes treatment program. By securing a world-class partner for our insulin-producing cells, we are taking a major step forward in our mission to offer an alternative to lifelong insulin injections. Our combined technologies have the potential to restore natural insulin production, delivering an innovative solution to diabetes management."
Dr. Brian Salmons, the CEO of Austrianova, elaborated on the advantages of their Cell-in-a-Box® technology, highlighting that clinical studies suggest encapsulated cells can live for extended durations post-implantation. The capsules not only protect the cells but also allow them to produce biologically active compounds effectively. "We believe our technology is ideally positioned to ensure that these implanted cells can deliver regulated, glucose-responsive insulin, greatly enhancing the treatment landscape for diabetes sufferers," Dr. Salmons commented.
The partnership is currently subject to the execution of definitive agreements and customary closing conditions. Avaí Bio anticipates that these essential documents will be finalized shortly, along with further announcements detailing the next steps of their collaboration.
The signing of this agreement not only represents a significant milestone for both companies but also holds great promise for the future of diabetes therapy. The introduction of infused, genetically programmed insulin-producing cells could revolutionize how diabetes is treated, thereby improving the quality of life for millions worldwide.
About Avaí Bio, Inc.: Avaí Bio is dedicated to identifying genetically modified cell lines and entering joint ventures and licensing agreements to roll out innovative therapies in cell-based medicine.
About Austrianova: Based in Singapore, Austrianova specializes in cell encapsulation and development of GMP-grade cell products. Their commitment to innovation is validated through numerous peer-reviewed studies and collaborations with global pharmaceutical firms.
This strategic partnership between Avaí Bio and Austrianova symbolizes a major leap in technology-driven advancements within biotechnology, pointing to a future where life-changing treatments for diabetes become a reality.
Avaí Bio has gained recognition for its innovative cell-based therapies targeting not only diabetes but also age-related disorders and anti-aging concerns. The focus of this newly formed partnership lies in their joint venture called Insulinova, which was established in late 2025. Insulinova aims to pioneer a cell-based therapy that integrates genetically modified cells that function as insulin producers with Austrianova’s proprietary Cell-in-a-Box® technology. This unique encapsulation technique promises to supply a constant flow of insulin in response to the body's varying needs, providing a more natural alternative for individuals afflicted with type 1 diabetes and those with insulin-dependent type 2 diabetes.
Chris Winter, CEO of Avaí Bio, expressed his enthusiasm for the recently signed agreement, stating, "This partnership is a pivotal advancement for Insulinova and our diabetes treatment program. By securing a world-class partner for our insulin-producing cells, we are taking a major step forward in our mission to offer an alternative to lifelong insulin injections. Our combined technologies have the potential to restore natural insulin production, delivering an innovative solution to diabetes management."
Dr. Brian Salmons, the CEO of Austrianova, elaborated on the advantages of their Cell-in-a-Box® technology, highlighting that clinical studies suggest encapsulated cells can live for extended durations post-implantation. The capsules not only protect the cells but also allow them to produce biologically active compounds effectively. "We believe our technology is ideally positioned to ensure that these implanted cells can deliver regulated, glucose-responsive insulin, greatly enhancing the treatment landscape for diabetes sufferers," Dr. Salmons commented.
The partnership is currently subject to the execution of definitive agreements and customary closing conditions. Avaí Bio anticipates that these essential documents will be finalized shortly, along with further announcements detailing the next steps of their collaboration.
The signing of this agreement not only represents a significant milestone for both companies but also holds great promise for the future of diabetes therapy. The introduction of infused, genetically programmed insulin-producing cells could revolutionize how diabetes is treated, thereby improving the quality of life for millions worldwide.
About Avaí Bio, Inc.: Avaí Bio is dedicated to identifying genetically modified cell lines and entering joint ventures and licensing agreements to roll out innovative therapies in cell-based medicine.
About Austrianova: Based in Singapore, Austrianova specializes in cell encapsulation and development of GMP-grade cell products. Their commitment to innovation is validated through numerous peer-reviewed studies and collaborations with global pharmaceutical firms.
This strategic partnership between Avaí Bio and Austrianova symbolizes a major leap in technology-driven advancements within biotechnology, pointing to a future where life-changing treatments for diabetes become a reality.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.